Option Care Health, Inc. (OPCH) Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
Sector: Services-Home Health Care Services
Industry: Medical - Care Facilities
Option Care Health, Inc. NASDAQ:OPCH Healthcare · Medical - Care Facilities
Mkt Cap $4.76B
Earnings Nov 4 · Today
CLOSED · Nov 3 $31.77 CLOSED · Nov 3 Prev close $31.69 Close $31.77 0.00% AH close $31.77 VOL 3.38M $ Vol $107.3M RVOL 0.45x
Mkt Cap $4.76B
VOL 3.38M sh
$ Vol $107.3M
RVOL 0.45×
Earnings Nov 4 · Today
Press Release
Are OPCH, PTC, RXO Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Option Care Health, PTC and RXO for potential securities-law violations and fiduciary breaches related to their pending take-private/sale transactions.
For OPCH, the firm is probing the proposed sale to CD&R and McKesson at $32.05 per share, and may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
This is a routine plaintiff-firm solicitation wired under the firm's own name with contact and contingency-fee language — not an issuer disclosure, a filed lawsuit, or a court action, and carries no new information about deal terms.
• 1h ago AI analysis › Press Release ⚠ 1
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, a plaintiff investor rights law firm, announced it is investigating Braze's sale to Salesforce for $47.50 per share in cash for potential securities-law violations and fiduciary breaches.
The release also covers investigations of Silence Therapeutics, Option Care Health, and RXO, and solicits shareholders to contact the firm on a contingency basis.
This is law-firm marketing rather than an issuer disclosure; it signals no change to the proposed Braze-Salesforce deal terms.
• 14d ago AI analysis › Press Release
Are DSGR, OPCH, PRTH, UTZ Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Distribution Solutions Group's $35.00-per-share cash sale to affiliates of LKCM Headwater Investments for potential fiduciary-duty breaches.
The multi-company release also targets Option Care Health, Priority Technology, and Utz Brands, and claims insiders may receive benefits unavailable to ordinary shareholders.
This is law-firm solicitation, not an issuer disclosure or court action; no new facts about the DSGR deal are revealed.
• 15d ago AI analysis › Press Release
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Boundless Bio's merger with Serapha Bio for potential securities-law violations and fiduciary breaches.
Boundless Bio shareholders are expected to own approximately 3.7% of the combined company upon closing, and the firm is soliciting shareholders to contact it on a contingent-fee basis.
This is law-firm marketing rather than an issuer disclosure; the same release also sweeps in investigations of OPCH, PCRX, and RXO deals.
• 22d ago AI analysis › Press Release ● Major ⚠ 3
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
McKesson and CD&R signed a definitive agreement to acquire Option Care Health for $32.05 per share, an enterprise value of approximately $5.8 billion and a 37% premium to OPCH's prior close.
McKesson will invest approximately $1.4 billion for a ~49% minority stake, with CD&R holding ~51%; the deal includes a framework for McKesson to later acquire CD&R's interest, subject to conditions and regulatory approvals.
Closing is expected in the first half of 2027; McKesson frames the deal as expanding its specialty-infusion and lower-cost community care footprint, and intends to use equity-method accounting for its stake.
• 28d ago AI analysis › Press Release
Option Care Health to Participate in Upcoming Investor Conferences
Option Care Health announced that CEO John Rademacher and CFO Meenal Sethna will participate in two upcoming investor conferences in New York City.
The executives appear at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026 at 10:45am ET, followed by the Deutsche Bank 2026 Healthcare Summit on September 16.
Webcast links and related presentation materials will be posted at investors.optioncarehealth.com; the notice contains no new financial or operational disclosures.
• 2mo ago AI analysis › Press Release ● Major
Option Care Health Announces Financial Results For The Second Quarter Ended June 30, 2026
Option Care Health reported Q2 revenue of $1.44 billion, up 1.9% year-over-year, while GAAP EPS grew 12.9% to $0.35 driven by operational efficiency.
The company generated $184 million in operating cash flow and repurchased $150 million of outstanding shares during the quarter, highlighting strong capital allocation.
Full-year 2026 guidance was updated to project revenue of $5.675 billion to $5.775 billion and adjusted EPS of $1.85 to $1.92, with low to mid single-digit sequential revenue growth expected in Q3.
• 3mo ago AI analysis › Press Release
Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
Option Care Health appointed Robert Okunski as Vice President of Investor Relations, effective May 26, 2026.
Okunski joins from Enhabit Home Health & Hospice, where he previously served as VP of Investor Relations, bringing over two decades of experience in the role.
He will lead the company’s IR strategy and serve as the primary liaison with the investment community, reporting to CFO Meenal Sethna.
• 4mo ago AI analysis › Press Release
Option Care Health Awarded TIME's World's Most Impactful Companies 2026 Ranking
Option Care Health was ranked No. 15 on TIME’s World’s Most Impactful Companies 2026 list.
The ranking, developed with Statista and The Upright Project, evaluates companies based on net-positive contributions across Society, Knowledge, Health, and Environment.
CEO John C. Rademacher cited the recognition as validation of the company’s mission to provide extraordinary care that changes lives.
• 5mo ago AI analysis › Press Release
Option Care Health to Participate in the Bank of America Health Care Conference
Option Care Health announced that management will participate in the Bank of America Health Care Conference in Las Vegas on May 12, 2026.
The event includes a fireside chat scheduled for 10:40am PT/1:40pm ET.
A live webcast of the session will be accessible through the company's investor relations website.
• 6mo ago AI analysis › Press Release ⚠ 3
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2026
Option Care Health reported Q1 revenue of $1.35 billion, up 1.3% year-over-year, with GAAP EPS rising 3.6% to $0.29.
Adjusted EBITDA declined 6.3% to $104.8 million and cash used in operations totaled $12.1 million, though the company offset this by repurchasing $17.5 million of stock and doubling its revolving credit facility to $850 million.
Full-year 2026 guidance sets revenue between $5.675 billion and $5.775 billion with adjusted EPS of $1.82 to $1.92, as management moves to re-accelerate growth following a mixed start to the year.
• 6mo ago AI analysis › 
